Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.58 |
| ▸ | KDR | P35968 | 6/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | FLT1 | P17948 | 1/20 | 0.52 |
| ▸ | FBP1 | P09467 | 1/20 | 0.52 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 2/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | GAK | O14976 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099428 | 0.92 | EGFR (0.65) | EGFRKDRKDM1ACLK1ABCG2 | |
| SCHEMBL4378175 | 0.89 | KDR (0.59) | EGFRKDRKDM1AFGFR1FLT1 | |
| SCHEMBL4374475 | 0.87 | EGFR (0.59) | EGFRKDRKDM1AFGFR1FLT1 | |
| SCHEMBL6099438 | 0.85 | EGFR (0.50) | EGFRKDRKDM1AFGFR1FLT1 | |
| SCHEMBL6098710 | 0.83 | RET (0.67) | EGFRKDRKDM1AFGFR1FLT1 | |
| SCHEMBL4380962 | 0.82 | EGFR (0.64) | EGFRKDRRET | |
| SCHEMBL4375005 | 0.82 | ERBB2 (0.63) | EGFRKDRFLT1CLK1ABCG2 | |
| SCHEMBL4378628 | 0.82 | KDR (0.70) | EGFRKDRFGFR1FLT1RET | |
| SCHEMBL6030597 | 0.82 | KDM1A (0.50) | EGFRKDRKDM1AFGFR1FLT1 | |
| SCHEMBL4373829 | 0.81 | EGFR (0.67) | EGFRKDRFGFR1FLT1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | EGFR 549/4885KDR 4/4885KDM1A 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.